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Abstract: Hepatocyte growth factor-like protein (HGFl) and its receptor, Recepteur 
d'Origine Nantais (RON), have been implicated in the development of wound chronicity. 
HGFl and RON expression was detected in acute wound tissue, chronic wound tissue and 
in normal skin using quantitative polymerase chain reaction (Q-PCR). HGFl and RON 
expression was also assessed in chronic healing and chronic non-healing wound tissues 
using Q-PCR and immunohistochemical staining. Expression was similarly detected in the 
HaCaT immortalized human keratinocyte cell line using reverse transcription polymerase 
chain reaction (RT-PCR). rhHGFl was used to assess the impact of this molecule on 
HaCaT cell functionality using in vitro growth assays and electric cell-substrate impendence 
sensing (ECIS) migration assays. HGFl and RON transcript expression were significantly 
increased in acute wound tissue compared to chronic wound tissue and were also elevated, 
though non-significantly, in comparison to normal skin. Minimal expression was seen in 
both healing and non-healing chronic wounds. Treatment of HaCaT cells with rhHGFl had 
no effect on growth rates but did enhance cell migration. This effect was abolished by the 
OPEN ACCESS
Biomedicines 2015, 3 111 
 
 
addition of a phospholipase C gamma (PLCγ) small molecule inhibitor. The increased 
expression of HGFl and RON in acute, healing wounds and the pro-migratory effect of 
HGFl in an in vitro human keratinocyte model, may indicate a role for HGFl in active 
wound healing. 
Keywords: hepatocyte growth factor-like (HGFl); macrophage stimulating protein (MSP); 
wound healing; human keratinocyte; HaCaT 
 
1. Introduction 
Cutaneous wound healing is a complex and multifactorial process. Numerous cellular and molecular 
players contribute to the ordered process of wound healing [1]. A number of local and systemic 
aberrations of these healing pathways have been implicated in wound chronicity [2]. Chronic non-healing 
wounds pose a significant problem to European healthcare providers, with an estimated 3.55–3.70 
patients per 1000 population currently undergoing wound treatment [3]. Poor wound healing is a 
source of significant morbidity, with a myriad of psychosocial implications. Research undertaken in 
our laboratory has focused on wound profiling and therapeutics [2], describing the action of several 
molecules on the activity of human epidermal cell lines at the wound edge [4–6]. 
Hepatocyte growth factor-like protein (HGFl), also known as macrophage stimulating protein (MSP) [7], 
was first characterized by its direct and indirect activation of the resident peritoneal macrophage [8]. 
The Recepteur d’Origine Nantais (ron) gene codes the receptor for this molecule (STK) and is activated 
when HGFl binds to its β-chain [9]. It has since been identified in numerous other physiological 
processes, including innate immunity [10], hepatocellular regeneration [11], neuroendocrine cell 
survival [12] and in utero development [8,9]. It has also been implicated in malignant transformation 
and metastatic potential of a number of tissue types—including liver [13], breast [14], colon [15], lung [16] 
and pancreas [17] and has been mapped in an at-risk subpopulation of inflammatory bowel disease  
sufferers [18]. Nanney et al. were the first to localize HGFl and its precursors to the human wound  
site [19]. Subsequently, the influence of HGFl on keratinocyte activity has been explored in multiple 
animal models. An Australasian group mapped the upregulation and co-localization of HGFl and the 
structurally related protein hepatocyte growth factor (HGF) in a rat model of excisional wound repair, 
differentiating a sub-role for HGFl in mature macrophage activation [20]. Whilst a 1998 paper by 
Bezerra et al. [21] denounced the role of HGFl in murine wound healing as non-essential in a knockout 
model, Wang et al. reported a definite concentration-dependent increase in primary murine keratinocyte 
proliferation with the addition of HGFl [22]. The same Chinese group reported the mandatory presence 
of phosphatidylinositol-3-kinase in HGFl-dependent human epithelial cell migration [23]. Santoro et al. 
postulated that the pro-migratory activity of HGFl in human epidermal wound healing was achieved by 
regulation of α6β4 integrin and α3β1 integrin in a critical signaling step [24]. 
HGFl belongs to the kringle protein family [8], which contains the only other recognized scatter 
factor HGF [25,26]. HGF is a pleiotropic factor effective in tissue homeostasis and response to insult, 
including tissue repair and epidermal wound healing. HGF and its isoforms act via the c-Met receptor 
tyrosine kinase. HGF, HGFl and their respective receptors have considerable structural similarities  
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and demonstrate cross-reactivity [27–30]. Crosstalk of RON and c-Met occurs in various cancer cell  
lines [31,32], with reciprocal trans-autophosphorylation in response to ligand binding. In addition, 
HGF/SF-activator proteases have been demonstrated to cleave pro-MSP, an inactive single chain 
precursor of HGFl [33]. 
Various cytoplasmic effector molecules have been mapped in downstream signaling and direct 
context-dependent receptor modification of both the HGF-c-Met and HGFl-RON systems. These 
include growth factor receptor-bound protein 2 (Grb2) [28], phosphatidylinositol 3-kinase (PI3K) [34] 
and phospholipase C gamma (PLC-γ) [27]. Whilst biological roles of HGF have been explored 
extensively in this laboratory [35,36], a role for the HGFl/RON pathway in human wound repair has 
yet to be clearly elucidated. Understanding this closely related scatter factor pathway will allow us to 
better characterize the HGF-c-Met axis and its secondary activities in the healing milieu. The current 
study aimed to examine the expression profile of HGFl in primary human wound tissue and explore 
the biological functionality of HGFl in an immortalized human keratinocyte cell line. We hypothesize 
a redundant activity of HGFl in modulation of epidermal wound healing. 
2. Results 
2.1. Expression Profile of HGFl/RON in Clinical Wound Samples 
The expression pattern of HGFl and RON were explored in the clinical cohorts available in this 
study. HGFl expression was found to be significantly higher in acute wound tissue (Median 0.058,  
IQR 0.013–4225) compared to chronic wound tissues (Median 0.0004, IQR 0.0002–0.0068, p < 0.05; 
Figure 1A). Acute wound tissue had higher HGFl expression than normal skin; however, this failed to 
reach significance. Similarly, no significant difference was observed between normal skin and chronic 
wound tissues. A similar pattern was observed in RON transcript expression (Figure 1B) where higher 
levels of transcript were seen in acute wound tissues than in chronic wound tissues and normal skin. 
Once again, this difference was only significant regarding acute wound tissues (Median 0.986,  
IQR 0.027–1.54) vs. chronic wound tissues (Median 0.0099, IQR 0.003–0.12, p < 0.05). 
Within the second wound tissue cohort, consistent with the first cohort, relatively low levels of both 
HGFl (Figure 1C) and RON (Figure 1D) were observed throughout the chronic wound samples  
(healed or non-healed). No significant differences in either HGFl (p = 0.66) or RON (p = 0.99) 
expression were apparent between the chronic healed and chronic non-healed samples. 
In tandem with transcript analysis, immunohistochemical staining of chronic healing and  
non-healing wound tissues revealed minimal staining for both HGFl and RON (Figure 2). HGFl 
expression was found to be negative in the epidermis of all tested chronic wound sections. Faint 
staining for HGFl was observed in the blood vessels of a small proportion of samples, although no 
difference between healing or non-healing chronic wounds was observed. Minimal staining for RON 
was observed in the basal nuclear region in many of the chronic wound samples though, again,  
no differences were observed between the healing and non-healing samples. When the leading wound 
edge and distal areas of the section towards normal skin were compared, no differences in the 
localization or intensity of RON staining were observed. 
Biomedicines 2015, 3 113 
 
 
 
 
Figure 1. Q-PCR analysis of HGFl and RON transcript expression in clinical wound 
samples. Expression levels of both HGFl (A) and RON (B) were significantly elevated in 
acute wound tissues compared to chronic wound tissues; whereas, similar levels were 
detected between chronic wound tissues and normal skin. Minimal expression of HGFl (C) 
and RON (D) were detected in chronic, healing/non-healing wound tissue, and whilst 
slightly elevated in non-healing chronic wounds, no significant differences were discovered 
between the two types of chronic wound tissue for either HGFl or RON. Median GAPDH 
ratio shown. * represents p < 0.05.  
2.2. Expression Pattern of HGFl/RON in Human Keratinocytes and Impact on Cell Growth 
Transcript analysis of human HaCaT keratinocytes (Figure 3A) demonstrated that this cell line 
displayed moderate expression of both HGFl and RON. Additionally, it also expressed the HGF 
receptor cMET at a high level, but not HGF at a detectable intensity. The impact of HGFl on HaCaT 
cell proliferation was explored through the additional rhHGFl, over a range of concentrations. 
Treatment with rhHGFl did not significantly impact the five-day growth rates of the HaCaT cell  
line (p > 0.05). 
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Figure 2. IHC staining for HGFl/RON in chronic healing/non-healing wound tissue. 
Minimal detection of both HGFl and RON were discovered in both types of chronic wound 
tissue. No substantial differences were seen in staining intensities of either HGFl or RON 
between the two types of chronic wound tissues. Negative controls indicate sections 
stained using secondary antibodies only. Positive controls show placental tissue stained 
using the respective antibodies. Representative images shown. 
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Figure 3. Expression analysis in human HaCaT keratinocytes and impact of HGFl on cell 
growth rates. HaCaT cells displayed strong expression for the HGF receptor cMET whilst 
not expressing HGF itself. Moderate expression was observed for HGFl, RON and PLCγ (A) 
Treatment of HaCaT keratinocytes with rhHGFl over a range of concentrations did not 
significantly impact on cell growth rates (B) Representative PCR images or Mean  
values ± SEM shown.  
2.3. HGFl Impacts on HaCaT Cell Migration 
The electric cell substrate impedance sensing (ECIS) system was used to detect the impact of 
rhHGFl on HaCaT cell migration following electrical wounding (Figure 4). Cell migration appeared to 
be enhanced following the addition of rhHGFl in a dose-dependent manner, with the most significant 
impact on cell migration being observed at the higher 50 ng/mL and 1000 ng/mL concentrations 
(Figure 4A). In order to explore potential pathways that may account for these pro-migratory effects of 
HGFl, a number of small molecule inhibitors were added, in addition to rhHGFl, to explore potential 
links between HGFl and these other signaling pathways. Of these pathways tested, HGFl appeared to 
have links with PLCγ signaling pathway. The pro-migratory effect of rhHGFl appeared to be 
completely stopped through the addition of a small molecule inhibitor to PLCγ, with levels of 
migration returning to approximately that of untreated control HaCaT cells (Figure 4B). 
  
Biomedicines 2015, 3 116 
 
 
 
Figure 4. ECIS analysis of the impact of HGFl on HaCaT cell migration. rhHGFl 
enhanced HaCaT cell migration rates over all concentrations tested, with the strongest 
response being observed at 50 ng/mL and 1000 ng/mL concentrations (A) Inhibition of 
PLCγ signaling inhibited the pro-migratory response elicited by rhHGFl (B). Representative 
images shown. 
3. Discussion 
This paper describes differential HGFl/RON expression in human wound tissue. HGFl/RON 
transcript expression was significantly greater in the “actively healing” acute wound tissues than in the 
“chronic” tissues and the relatively quiescent “normal skin” tissues. HGFl/RON expression was 
generally low in both the “healing” and “non-healing” chronic group. Immunohistochemistry showed 
low-level HGFl/RON expression in chronic wound samples, with little variation in expression between 
the chronic healing and non-healing groups. Both HGFl and RON were seen to be expressed in the 
immortalized human keratinocyte cell line. When HGFl was added to HaCaT cells in an in vitro model 
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of wounding, a concentration-dependent pro-migratory effect was observed. The addition of a PLCγ 
inhibitor reversed the rate of migration to baseline levels at all concentrations of added HGFl.  
HGFl had no effect on cellular growth. 
To the best of our knowledge, this is the first paper to describe differential expression of HGFl in 
clinical wound samples. Greater expression in acute compared to chronic wound edge tissues suggests 
a role for HGFl in acute wound healing. The temporal correlation of this upregulation implicates a role 
for HGFl in re-epithelization. Whilst causality is impossible to prove from these data, it may be that 
errors in an HGFl-dependent pathway contribute to wound chronicity. The expression of HGFl/RON 
in both the healing and non-healing chronic wound samples remained considerably below that of the 
acutely healing cohort. This reinforced a potential role for HGFl in acute wound healing. 
The effect of HGFl on an immortalized human keratinocyte cell line was also analyzed.  
The concentration-dependent pro-migratory effect of HGFl observed suggests a role for HGFl in 
perpetuating cell migration during epithelization. Our paper supports the findings of Cowin et al.  
2001 [20] who described increased HGFl expression in a rodent model of acute wound healing.  
This group co-localized HGFl to a monocyte subtype, with implications to tissue remodeling.  
Whilst Bezerra et al. 1998 [21] reported HGFl to be non-essential in the murine wound healing pathway, 
we demonstrated a definite augmentation of epithelial migration with the addition of recombinant 
HGFl and a definite increase in HGFl expression in an acutely healing clinical wound cohort. Wang et al. 
1996 [23] also found a pro-migratory role of HGFl in a murine in vitro model. However, we were 
unable to replicate reported increases in cell population growth in our human keratinocyte cell line. 
The ECIS model used permitted multiple simultaneous experimental repeats with high accuracy 
estimation of migration distance above that of traditional scratch wound healing models. However,  
the use of an immortalized cell line for a wound healing study, although well documented by this  
lab [4,37], may lack translatability. Exploration of the role of HGFl in clinical wound healing may 
benefit from the use of a primary human keratinocyte cell line. 
PLCγ appears to be a key downstream effector via which HGFl retains its pro-migratory effect. 
Future work is required to substantiate this finding. Wang et al. 1996 [23] noted a similar effect with 
the addition of a phosphatidylinositol-3 kinase inhibitor. Use of other single molecular inhibitors,  
or combinations of pathway inhibitors, in ECIS wounding models would help better delineate HGFl’s 
clinical and therapeutic roles. This work is currently ongoing, though the observed relationship between 
HGFl and PLCγ are of interest, given the role of PLCγ signaling in cell motility, cancer progression 
and invasion, and its links to HGF-induced cancer invasion and motility [38,39]. Our current data 
implies that PLCγ may act in a similar fashion as that seen in cancer cells’ responses to HGF, acting to 
facilitate HGFl pro-migratory effects in keratinocytes. In addition, although alluded to herein, the 
exploration of the interaction of HGFl with components of the extracellular matrix, including α6β4 
integrin and α3β1 integrin, has been overlooked and warrants further investigation. 
Epidermal wound healing is a complex and multifactorial process. HGFl is upregulated in acute 
wound tissue, displaying normal healing in comparison to chronic, non-healing wound tissue.  
HGFl may have a role in augmenting clinical wound healing through a pro-migratory effect on human 
epithelial cell lines. 
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4. Materials and Methods 
4.1. Wound Edge Biopsies 
Two cohorts of wound edge tissue were used for analysis, collected from patients in attendance at 
multidisciplinary wound-healing clinics at the University Hospital of Wales, Cardiff. For the first 
cohort (South East Wales Research Ethics Committee reference number 04/WSE02/10), chronic 
wound tissue was obtained from the periphery of chronic leg ulcers of proven venous aetiology that 
were refractory to six months of standard treatment. Acute wound tissue was obtained from the edge of 
surgical wounds (excision of pilonidal disease) within 6 weeks of the procedure. Normal skin was 
taken from the inner aspect of the upper arm of healthy volunteers under local anesthetics. All wounds 
sampled were deemed non-infected by an overseeing physician. Ten acute samples, 10 normal skin 
samples and 14 chronic samples were used herein. Details of the patient cohort and biopsy techniques 
have been described elsewhere [36]. 
For the second cohort, wound edge tissue from patients with chronic venous leg ulcers were 
obtained (South East Wales Research Ethics Committee reference number 09/WSE02/59). Wounds 
were measured at the time of the biopsy, treated as per best medical treatment, and re-measured at  
3 months. Static or enlarging wounds were deemed chronic non-healing, whilst those reducing in size 
were deemed chronic healing. This cohort consisted of 20 healing chronic wounds and 51 non-healing 
chronic wounds, as described previously [37]. 
Core biopsies were stored initially at −80 °C, before submersion in liquid nitrogen for storage  
prior to analysis. They were then sectioned on a Leica cyrostat (Leica Microsystems (UK) Ltd.,  
Milton Keynes, UK) to a thickness of 7 µm for immunohistochemical staining and 20 µm for RNA 
extraction (multiple sections), reverse transcription and quantitative polymerase chain reaction (Q-PCR) 
transcript analysis. 
4.2. Materials for Cell Culture 
All materials and reagents were purchased from Sigma–Aldrich (Poole, UK), unless otherwise 
specified. The immortalized human keratinocyte cell line “HaCaT” (German Cancer Institute, 
Heidelberg, Germany) was used herein. Cells were cultured in DMEM/Ham’s F12 with L-Glutamine 
medium, supplemented with added amphotericin B, streptomycin, penicillin and 10% fetal calf serum. 
Recombinant human HGFl (rhHGFl) was obtained from R&D systems (Abingdon, UK).  
The biological functionality of HGFl was interrogated with the addition of rhHGFl over a range of 
concentrations and compared to an untreated control. PLCγ inhibitor (U73122) was purchased from 
Calbiochem (Merck Chemicals Ltd., Nottingham, UK). 
4.3. RNA Extraction, Reverse Transcription Polymerase Chain Reaction (RT-PCR) and  
Quantitative RT-PCR 
Cells were lysed in TRI reagent, and multiple sections of wound tissue were homogenized using  
a handheld homogenizer (Cole Palmer, London, UK) in ice-cold TRI reagent. RNA extraction was 
performed on both cells and wound tissue as per manufacturer’s guidelines. Extracted RNA was  
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re-suspended in DEPC water, quantified using a spectrophotometer (WPA UV 1101, Biotech, 
Cambridge, UK) and standardized. cDNA was generated via reverse transcription of the RNA template 
using a High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Paisley, UK). Polymerase 
chain reaction (PCR) was performed in a T-Cy Thermocycler (Creacon Technologies Ltd., Emmen, 
The Netherlands) using GoTaq master mix (Promega, Hampshire, UK) under the following conditions: 
initial denaturing (94 °C, 5 min), followed by 32–34 cycles of denaturing, annealing and elongation 
(94 °C for 30 s, 55 °C for 40 s, 72 °C for 50 s), and final extension at 72 °C for 10 min before holding 
at 4 °C. Details of primers used are in Table 1. PCR products were loaded onto an agarose gel, 
electrophoretically separated, stained in SYBR Safe and visualized under blue light. Images were 
obtained using a camera mounted to a U-Genius 3 Gel documentation system (Syngene, Cambridge, 
UK). For the cohort tissue samples Q-PCR was performed. The Q-PCR assay used the Amplifluor 
(TM) detection system (Intergen Inc., New York, NY, USA) as previously described [40,41]. cDNA 
was added to Hotstart Q-master mix (AbGene), 10 pmol forward primer, 1 pmol reverse primer 
(containing the z sequence) and 10 pmol of the FAM-tagged universal Z probe (Intergen Inc., New York, 
NY, USA). Primer sequences used are detailed in Table 1. Cycle thresholds and conditions used 
replicated those previously described [6]. An internal standard was simultaneously amplified with the 
samples to allow a transcript copy number to be calculated using the StepOne™ software version 2.2.2 
(Life Technologies, Paisley, UK). 
Table 1. Primers used for polymerase chain reaction (PCR) and quantitative polymerase 
chain reaction (Q-PCR) (ACTGAACCTGACCGTACA is the z sequence). 
Primer Forward Reverse 
HGFl AGGTGCAGTTTGAGAAGTGT CTGTGTCATTACCCGTACCT 
RON CATCCACCCAGTGCCAAC ACTGAACCTGACCGTACACCACACAGTCAGCCACAG 
cMET ACTGAACCTGACCGTACAGAGCCAA
AGTCCTTTCAT 
ATCGAATGCAATGGATGAT 
HGF TACTGCAGACCAATGTGCTA ACTGAACCTGACCGTACAGCATTGTTTTCTCGCTTTAT 
PLCγ AGAACGACATCAGCAACTCT GCATATGAGTTGGGTTCATT 
GAPDH  
(PCR) 
AGCTTGTCATCAATGGAAAT CTTCACCACCTTCTTGATGT 
HGFl GACCAGGCGCCATCAATC ACTGAACCTGACCGTACACTTGGAACGCCGCTGATC 
GAPDH  
(Q-PCR) 
CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG 
4.4. Immunohistochemical Staining of Wound Tissue 
Serial frozen sections of wound tissue were fixed in dried acetone (Fisher, UK) before being 
hydrated in tris buffered saline (TBS) wash buffer and incubated in a 10% horse serum wash buffer for 
one hour. Anti-HGFL (R&D 352-MS) or anti-RON (R&D AF691) primary antibodies were added to 
the sections at a dilution of 1:100 and incubated for 1 h. The sections were then washed in TBS wash 
buffer 4 times and antibody localization was identified with a standard streptavidin-biotin peroxidase  
technique (Vector Laboratories, Peterborough, UK). The final reaction product was developed with  
3,3'-diaminobenzidine (DAB), and then the sections were counterstained with Mayer’s haematoxylin 
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(Merck, Germany), washed in running tap water, dehydrated through a graded series of alcohol, 
cleared in xylene, mounted in DPX mounting medium (Merck, Germany) and observed under a 
microscope. Any positive staining was seen as a brown-black deposit, whilst negative areas were 
identified as blue counterstained nucleated cells. 
4.5. In Vitro Growth Assay 
Three thousands cells were seeded into each well of two 96-well plates with or without the addition 
of HGFl at a defined concentration. The plates were incubated at 37 degrees for 1 or 5 days as 
appropriate. At their respective end-points the cells were fixed with 4% formaldehyde (v/v),  
stained with 0.5% (w/v) crystal violet solution and treated with 10% acetic acid (v/v). Subsequently, 
the solution was analyzed using a 96 well plate spectrophotometric Bio-Tek ELx800177 multi-plate 
reader (Bio-Tek, Winooski, VT, USA) at 540 nm wavelength and cell density calculated indirectly 
based on absorbance. 
4.6. Electric Cell–Substrate Impedance Sensing Analysis of Cellular Migration 
The electric cell–substrate impedance sensing (ECIS) system (Applied Biophysics, Troy, NJ, USA) 
was also used to analyze HaCaT migration, using methods previously described [42]. Eighty thousands 
(80,000) cells were seeded in HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffered 
medium, with or without the respective HGFl treatment, and incubated until a confluent monolayer 
had been formed. The monolayer was wounded electrically using the manufacturer’s “wound” 
function. As cells migrated back towards the electrode, a change in cell-substrate resistance was 
detected. This rate of change was measured using the ECIS software provided, providing a surrogate 
for rate of migration. 
4.7. Statistical Analysis 
Statistical analysis was undertaken using the Sigmaplot 11 statistical package (Systat Software Inc., 
London, UK). Data was compared using Mann Whitney, ANOVA on RANKS or ANOVA statistical 
tests depending on data normality. A minimum number of three repeats for experimental data were 
preformed. A value of p < 0.05 was taken as statistically significant. 
Acknowledgments 
This work was supported by a summer studentship grant from the INSPIRE special project fund of 
the Academy of Medical Sciences, London. The authors wish to thank the A4B Scheme of the  
Welsh Government, Ser Cymru Welsh Life Science Network and Cancer Research Wales for supporting  
this study.  
Author Contributions 
W.G.J. and K.G.H. contributed to study design. J.C.G., A.J.S., F.R., and D.C.B. contributed to the 
experimental work, data analysis and proofing of the manuscript. J.C.G. wrote the manuscript. 
  
Biomedicines 2015, 3 121 
 
 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Baum, C.L.; Arpey, C.J. Normal cutaneous wound healing: Clinical correlation with cellular and 
molecular events. Dermatol. Surg. 2005, 31, 674–686; discussion 686. 
2. Harding, K.G.; Morris, H.L.; Patel, G.K. Science, medicine and the future: Healing chronic wounds. 
BMJ 2002, 324, 160–163. 
3. Posnett, J.; Gottrup, F.; Lundgren, H.; Saal, G. The resource impact of wounds on health-care 
providers in europe. J. Wound Care 2009, 18, 154–161. 
4. Bosanquet, D.C.; Ye, L.; Harding, K.G.; Jiang, W.G. Expressed in high metastatic cells (ehm2) is 
a positive regulator of keratinocyte adhesion and motility: The implication for wound healing.  
J. Dermatol. Sci. 2013, 71, 115–121. 
5. Jiang, W.G.; Ye, L.; Patel, G.; Harding, K.G. Expression of waves, the wasp (wiskott-aldrich 
syndrome protein) family of verprolin homologous proteins in human wound tissues and the 
biological influence on human keratinocytes. Wound Repair Regen. 2010, 18, 594–604. 
6. Sanders, A.J.; Jiang, D.G.; Jiang, W.G.; Harding, K.G.; Patel, G.K. Activated leukocyte cell 
adhesion molecule impacts on clinical wound healing and inhibits hacat migration. Int. Wound J. 
2011, 8, 500–507. 
7. Bezerra, J.A.; Han, S.; Danton, M.J.; Degen, S.J. Are hepatocyte growth factor-like protein and 
macrophage stimulating protein the same protein? Protein Sci. 1993, 2, 666–668. 
8. Skeel, A.; Yoshimura, T.; Showalter, S.D.; Tanaka, S.; Appella, E.; Leonard, E.J. Macrophage 
stimulating protein: Purification, partial amino acid sequence, and cellular activity. J. Exp. Med. 
1991, 173, 1227–1234. 
9. Leonard, E.J. Biological aspects of macrophage-stimulating protein (MSP) and its receptor.  
Ciba Found. Symp. 1997, 212, 183–191; discussion 192–187. 
10. Wilson, C.B.; Ray, M.; Lutz, M.; Sharda, D.; Xu, J.; Hankey, P.A. The RON receptor tyrosine 
kinase regulates ifn-gamma production and responses in innate immunity. J. Immunol. 2008, 181, 
2303–2310. 
11. Bezerra, J.A.; Laney, D.W., Jr.; Degen, S.J. Increased expression of mrna for hepatocyte growth 
factor-like protein during liver regeneration and inflammation. Biochem. Biophys. Res. Commun. 
1994, 203, 666–673. 
12. Willett, C.G.; Smith, D.I.; Shridhar, V.; Wang, M.H.; Emanuel, R.L.; Patidar, K.; Graham, S.A.; 
Zhang, F.; Hatch, V.; Sugarbaker, D.J.; et al. Differential screening of a human chromosome 3 
library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in 
injured lung. Possible implications for neuroendocrine cell survival. J. Clin. Investig. 1997, 99, 
2979–2991. 
13. Zhu, M.; Paddock, G.V. Expression of the hepatocyte growth factor-like protein gene in human 
hepatocellular carcinoma and interleukin-6-induced increased expression in hepatoma cells. 
Biochim. Biophys. Acta 1999, 1449, 63–72. 
Biomedicines 2015, 3 122 
 
 
14. Kretschmann, K.L.; Eyob, H.; Buys, S.S.; Welm, A.L. The macrophage stimulating protein/RON 
pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer 
progression. Curr. Drug Targets 2010, 11, 1157–1168. 
15. Wang, M.H.; Wang, D.; Chen, Y.Q. Oncogenic and invasive potentials of human  
macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis  
2003, 24, 1291–1300. 
16. Kanteti, R.; Krishnaswamy, S.; Catenacci, D.; Tan, Y.H.; E.L.-Hashani, E.; Cervantes, G.;  
Husain, A.N.; Tretiakova, M.; Vokes, E.E.; Huet, H.; et al. Differential expression of RON in 
small and non-small cell lung cancers. Genes Chromosomes Cancer 2012, 51, 841–851. 
17. Yu, P.T.; Babicky, M.; Jaquish, D.; French, R.; Marayuma, K.; Mose, E.; Niessen, S.; Hoover, H.; 
Shields, D.; Cheresh, D.; et al. The RON-receptor regulates pancreatic cancer cell migration 
through phosphorylation-dependent breakdown of the hemidesmosome. Int. J. Cancer 2012, 131, 
1744–1754. 
18. Kauder, S.E.; Santell, L.; Mai, E.; Wright, L.Y.; Luis, E.; N’Diaye, E.N.; Lutman, J.; Ratti, N.;  
Sa, S.M.; Maun, H.R.; et al. Functional consequences of the macrophage stimulating protein 689c 
inflammatory bowel disease risk allele. PLoS One 2013, 8, e83958. 
19. Nanney, L.B.; Skeel, A.; Luan, J.; Polis, S.; Richmond, A.; Wang, M.H.; Leonard, E.J.  
Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its 
receptor in tissue injury. J. Investig. Dermatol. 1998, 111, 573–581. 
20. Cowin, A.J.; Kallincos, N.; Hatzirodos, N.; Robertson, J.G.; Pickering, K.J.; Couper, J.;  
Belford, D.A. Hepatocyte growth factor and macrophage-stimulating protein are upregulated 
during excisional wound repair in rats. Cell Tissue Res. 2001, 306, 239–250. 
21. Bezerra, J.A.; Carrick, T.L.; Degen, J.L.; Witte, D.; Degen, S.J. Biological effects of targeted 
inactivation of hepatocyte growth factor-like protein in mice. J. Clin. Investig. 1998, 101, 1175–1183. 
22. Wang, M.H.; Dlugosz, A.A.; Sun, Y.; Suda, T.; Skeel, A.; Leonard, E.J. Macrophage-stimulating 
protein induces proliferation and migration of murine keratinocytes. Exp. Cell Res. 1996, 226,  
39–46. 
23. Wang, M.H.; Montero-Julian, F.A.; Dauny, I.; Leonard, E.J. Requirement of phosphatidylinositol-3 
kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 
1996, 13, 2167–2175. 
24. Santoro, M.M.; Gaudino, G.; Marchisio, P.C. The MSP receptor regulates alpha6beta4 and 
alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev. Cell 2003, 5, 257–271. 
25. Yoshimura, T.; Yuhki, N.; Wang, M.H.; Skeel, A.; Leonard, E.J. Cloning, sequencing, and 
expression of human macrophage stimulating protein (MSP, mst1) confirms MSP as a member of 
the family of kringle proteins and locates the MSP gene on chromosome 3. J. Biol. Chem. 1993, 
268, 15461–15468. 
26. Han, S.; Stuart, L.A.; Degen, S.J. Characterization of the dnf15s2 locus on human chromosome 3: 
Identification of a gene coding for four kringle domains with homology to hepatocyte growth 
factor. Biochemistry 1991, 30, 9768–9780. 
27. Iwama, A.; Yamaguchi, N.; Suda, T. STK/RON receptor tyrosine kinase mediates both apoptotic 
and growth signals via the multifunctional docking site conserved among the hgf receptor family. 
EMBO J. 1996, 15, 5866–5875. 
Biomedicines 2015, 3 123 
 
 
28. Chaudhuri, A.; Xie, M.H.; Yang, B.; Mahapatra, K.; Liu, J.; Marsters, S.; Bodepudi, S.; Ashkenazi, A. 
Distinct involvement of the gab1 and grb2 adaptor proteins in signal transduction by the related 
receptor tyrosine kinases RON and met. J. Biol. Chem. 2011, 286, 32762–32774. 
29. Ronsin, C.; Muscatelli, F.; Mattei, M.G.; Breathnach, R. A novel putative receptor protein 
tyrosine kinase of the met family. Oncogene 1993, 8, 1195–1202. 
30. Yao, H.P.; Zhou, Y.Q.; Zhang, R.; Wang, M.H. MSP-RON signalling in cancer: Pathogenesis and 
therapeutic potential. Nat. Rev. Cancer 2013, 13, 466–481. 
31. Follenzi, A.; Bakovic, S.; Gual, P.; Stella, M.C.; Longati, P.; Comoglio, P.M. Cross-talk between 
the proto-oncogenes met and RON. Oncogene 2000, 19, 3041–3049. 
32. Benvenuti, S.; Lazzari, L.; Arnesano, A.; Li Chiavi, G.; Gentile, A.; Comoglio, P.M. RON kinase 
transphosphorylation sustains met oncogene addiction. Cancer Res. 2011, 71, 1945–1955. 
33. Kawaguchi, M.; Orikawa, H.; Baba, T.; Fukushima, T.; Kataoka, H. Hepatocyte growth factor 
activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J. 
2009, 276, 3481–3490. 
34. Xiao, Z.Q.; Chen, Y.Q.; Wang, M.H. Requirement of both tyrosine residues 1330 and 1337 in the 
c-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. 
Biochem. Biophys. Res. Commun. 2000, 267, 669–675. 
35. Conway, K.; Price, P.; Harding, K.G.; Jiang, W.G. The molecular and clinical impact of 
hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair 
Regen. 2006, 14, 2–10. 
36. Conway, K.; Ruge, F.; Price, P.; Harding, K.G.; Jiang, W.G. Hepatocyte growth factor regulation: 
An integral part of why wounds become chronic. Wound Repair Regen. 2007, 15, 683–692. 
37. Bosanquet, D.C.; Harding, K.G.; Ruge, F.; Sanders, A.J.; Jiang, W.G. Expression of il-24 and  
il-24 receptors in human wound tissues and the biological implications of il-24 on keratinocytes.  
Wound Repair Regen. 2012, 20, 896–903. 
38. Lattanzio, R.; Piantelli, M.; Falasca, M. Role of phospholipase c in cell invasion and metastasis. 
Adv. Biol. Regul. 2013, 53, 309–318. 
39. Davies, G.; Martin, T.A.; Ye, L.; Lewis-Russell, J.M.; Mason, M.D.; Jiang, W.G. Phospholipase-c 
gamma-1 (plcgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and 
migration without affecting the growth of prostate cancer cells. Urol. Oncol. 2008, 26, 386–391. 
40. Jiang, W.G.; Hiscox, S.; Hallett, M.B.; Scott, C.; Horrobin, D.F.; Puntis, M.C. Inhibition of 
hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by 
gamma-linolenic acid. Br. J. Cancer 1995, 71, 744–752. 
41. Parr, C.; Watkins, G.; Mansel, R.E.; Jiang, W.G. The hepatocyte growth factor regulatory factors 
in human breast cancer. Clin. Cancer Res. 2004, 10, 202–211. 
42. Wegener, J.; Keese, C.R.; Giaever, I. Electric cell-substrate impedance sensing (ECIS) as a 
noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. Exp. Cell Res. 
2000, 259, 158–166. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
